|

Daunorubicin Clinical Trials

25 actively recruiting trials across 10 locations

Also known as: Cerubidine, DNR, Daunomycin, Daunorrubicina, Leukaemomycin C, Rubidomycin, Rubomycin C, all-trans retinoic acid, daunomycin, daunorubicin plus cytarabine, realgar-indigo naturalis formula

Other12 trials

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
Phase 2
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Phase 2
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Phase 3
MRD-positive AML Clinical Study
N/A
Optimum Induction Therapy of Low-risk APL
N/A
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Phase 2
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Phase 2/3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3
VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/3
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2

Birmingham, Alabama2 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 3
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

San Diego, California2 trials

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital

Phase 2
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Rady Children's Hospital

Phase 4

Portland, Oregon2 trials

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 2
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1

Gilbert, Arizona1 trial

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona1 trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Mayo Clinic - Phoenix

Phase 1

Duarte, California1 trial

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

City of Hope

Phase 2

Orange, California1 trial

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 1

Boston, Massachusetts1 trial

Revumenib in Combination With 7+3 + Midostaurin in AML

Brigham and Women's Hospital

Phase 1

The Bronx, New York1 trial

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM)

Phase 1

Tulsa, Oklahoma1 trial

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Saint Francis Children's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.